A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis.

Trial Profile

A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Juvenile rheumatoid arthritis; Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLIPPER
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Mar 2016 Results published in The Journal of Rheumatology
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00962741).
    • 05 Jun 2012 Actual patient number is 127 according to ClinicalTrials.gov (Parent trial: NCT00962741).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top